Daily Archives: September 14, 2018

I read with great interest the recent review by Bjarnason et al1 in the Journal. Understanding the specific properties and potential for damage to various nonsteroidal anti-inflammatory drugs (NSAIDs) is important, as exemplary detailed and discussed … Continue reading →

Nonalcoholic steatohepatitis (NASH) is a leading cause of liver transplantation and many trials are underway to evaluate potential therapies. The farnesoid X receptor ligand obeticholic acid in NASH treatment trial evaluated the effects of obeticholic acid vs placebo on histologic response (defined as decrease in nonalcoholic fatty liver disease activity score [NAS] by ≥2, with no worsening of fibrosis); 45% of patients had a histologic response to obeticholic acid (25 mg) and 21% had a response to placebo (P<.01). Continue reading →

With great interest we have read the recent article from Aleksei Suslov et al,1 wherein the authors showed patients with chronic hepatitis B virus (HBV) infection do not exhibit innate immune response, however this response observed upon induction of … Continue reading →

In their excellent study D’Haens et al1 tested the hypothesis that in patients with active Crohn’s disease targeting infliximab prespecified trough levels (TL) produces higher rates of clinical and endoscopic remission compared with adapting infli… Continue reading →

We read with great interest the recently published paper from Dolai et al,1 in which they demonstrated novel mechanistic insights regarding the role of syntaxin 2 (STX2), a t-SNARE protein, in the pathogenesis of pancreatitis. Pancreatitis is an infla… Continue reading →